The Lancet Neurology
Fecha de publicación: August 2018
DOI: https://doi.org/10.1016/S1474-4422(18)30248-5
Autores: Gabrielle Macaron, Jeffrey A Cohen.
Background: More than a dozen disease-modifying therapies (DMTs) are now available to treat relapsing multiple sclerosis, with varied mechanisms of action, routes of administration, efficacy, safety, and tolerability.
